Novarex노바렉스
194700 · KOSDAQ · ₩194700 · 노바렉스
₩8,970▼ ₩170 (1.86%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩403B | ₩296B | ₩301B | ₩281B | ₩278B |
| Cost of sales | ₩335B | ₩255B | ₩258B | ₩241B | ₩237B |
| Gross profit | ₩68B | ₩41B | ₩43B | ₩40B | ₩41B |
| Operating income | ₩42B | ₩22B | ₩26B | ₩25B | ₩30B |
| Net income | ₩35B | ₩22B | ₩22B | ₩20B | ₩26B |
| Net income to shareholders | ₩35B | ₩22B | ₩22B | ₩20B | ₩26B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩357B | ₩288B | ₩264B | ₩270B | ₩254B |
| Current assets | ₩210B | ₩140B | ₩121B | ₩129B | ₩111B |
| Cash and equivalents | ₩48B | ₩30B | ₩30B | ₩26B | ₩18B |
| Total liabilities | ₩105B | ₩69B | ₩64B | ₩89B | ₩114B |
| Current liabilities | ₩94B | ₩66B | ₩60B | ₩72B | ₩89B |
| Borrowings | ₩34B | ₩22B | ₩23B | ₩45B | ₩54B |
| Total equity | ₩252B | ₩219B | ₩200B | ₩181B | ₩140B |
| Shareholders' equity | ₩252B | ₩219B | ₩200B | ₩181B | ₩140B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩16B | ₩13B | ₩26B | ₩20B | ₩24B |
| Capital spending | ₩10B | ₩6.7B | ₩8.2B | ₩16B | ₩37B |
| Free cash flow | ₩6.1B | ₩5.8B | ₩18B | ₩4.2B | −₩13B |
| Dividends paid | ₩3.5B | ₩3.5B | ₩2.7B | ₩2.4B | ₩2.4B |
Consolidated where available. Amounts in won.
Also known as: Novarex / 노바렉스 / 194700 / KRX:194700
Source: KRX statistical information